Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Sun Pharma Inds
Consolidated Standalone

Sun Pharma Inds.

₹1493.4 -28.2 | 1.9%

Market Cap ₹358305 Cr.

Stock P/E 40.2

P/B 5.7

Current Price ₹1493.4

Book Value ₹ 260

Face Value 1

52W High ₹1638.7

Dividend Yield 0.77%

52W Low ₹ 922.5

Edit Ratio

Sun Pharma Inds. Research see more...

Overview Inc. Year: 1993Industry: Pharmaceuticals & Drugs

Sun Pharmaceutical Industries Ltd is an multinational pharmaceutical company. The Company is engaged in the business of manufacturing, growing and marketing various generic formulations. It produces a portfolio of generic and speciality medicines concentrated on a spectrum of chronic and acute treatments. The Company's product portfolio consists of generics, branded generics, over-the-counter (OTC)/client healthcare products, speciality, anti-retrovirals (ARVs), active pharmaceutical elements (APIs) and intermediates. Its over the counter brands includes Faringosept , Revital, and Volini. The Company offers its products in types of dosage forms, which includes capsules, pills, sprays, injectables, inhalers, ointments, creams and beverages. Its portfolio of speciality merchandise, branded generics are available in 100 international locations. The Company operates production sites across 6 continents.

Read More..

Sun Pharma Inds. Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Sun Pharma Inds. Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 9626 9863 9447 10762 10952 11241 10931 11941 12192 12381
Other Income 223 433 275 148 85 174 373 206 294 375
Total Income 9849 10296 9721 10910 11038 11415 11304 12147 12486 12755
Total Expenditure 6996 7257 7267 8023 7996 8237 8129 8611 9013 9028
Operating Profit 2853 3039 2454 2887 3042 3178 3175 3536 3473 3727
Interest 36 19 37 14 19 46 93 81 49 35
Depreciation 530 554 556 588 610 660 672 651 633 622
Exceptional Income / Expenses 0 0 -3936 0 0 0 -171 -323 0 -70
Profit Before Tax 2287 2466 -2076 2285 2412 2471 2240 2481 2791 3000
Provision for Tax 198 335 147 189 152 283 223 468 390 432
Profit After Tax 2089 2131 -2222 2096 2260 2188 2017 2013 2401 2568
Adjustments -42 -72 -55 -35 2 -22 -32 10 -25 -44
Profit After Adjustments 2047 2059 -2277 2061 2262 2166 1984 2023 2376 2524
Adjusted Earnings Per Share 8.5 8.6 -9.5 8.6 9.4 9 8.3 8.4 9.9 10.5

Sun Pharma Inds. Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 11300 16080 27392 28109 31308 26416 29066 32838 33498 38654 43886 47445
Other Income 388 552 566 658 1030 912 1059 652 859 1437 820 1248
Total Income 11688 16633 27958 28767 32338 27328 30125 33489 34357 40092 44706 48692
Total Expenditure 6404 9081 19543 19950 21626 20881 22792 25863 25030 28773 32424 34781
Operating Profit 5284 7552 8414 8817 10712 6447 7333 7626 9327 11319 12281 13911
Interest 43 44 579 523 400 518 555 303 141 127 172 258
Depreciation 336 409 1195 1038 1265 1500 1753 2053 2080 2144 2529 2578
Exceptional Income / Expenses -584 -2517 -238 -685 0 -951 -1214 -261 -4306 -4567 -171 -564
Profit Before Tax 4321 4581 6403 6571 9048 3479 3810 5010 2799 4481 9408 10512
Provision for Tax 846 702 915 914 1212 911 601 823 515 1076 848 1513
Profit After Tax 3476 3879 5488 5657 7836 2568 3209 4187 2285 3406 8561 8999
Adjustments -493 -738 -949 -1111 -872 -472 -544 -422 619 -133 -87 -91
Profit After Adjustments 2983 3141 4539 4546 6964 2096 2665 3765 2904 3273 8474 8907
Adjusted Earnings Per Share 14.4 15.2 21.9 18.9 29 8.7 11.1 15.7 12.1 13.6 35.3 37.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 14% 10% 11% 15%
Operating Profit CAGR 8% 17% 14% 9%
PAT CAGR 151% 27% 27% 9%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 56% 29% 28% 9%
ROE Average 16% 10% 9% 15%
ROCE Average 17% 11% 10% 16%

Sun Pharma Inds. Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 14990 18525 25638 32982 36640 38314 41409 45264 46463 48011 55995
Minority's Interest 1635 1921 2851 4085 3791 3884 3314 3860 3017 3055 3320
Borrowings 115 49 1368 3110 1436 1772 1523 2029 898 230 0
Other Non-Current Liabilities 84 1700 967 -941 -836 -1726 -1446 -1783 -2413 -1546 -1643
Total Current Liabilities 2841 5990 16147 13144 17887 19864 17340 15706 16146 17208 19906
Total Liabilities 19665 28184 46972 52381 58917 62109 62139 65077 64110 66958 77579
Fixed Assets 5647 6817 12682 15872 17675 18853 21837 22847 21553 22665 24420
Other Non-Current Assets 2514 2680 5373 6568 8289 11620 9233 10576 12115 9428 13276
Total Current Assets 11503 18686 28916 29934 32947 31636 31069 31654 30442 34865 39862
Total Assets 19665 28184 46972 52381 58917 62109 62139 65077 64110 66958 77579

Sun Pharma Inds. Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 1753 2069 4359 7183 8032 8642 7906 7062 5677 6273 4508
Cash Flow from Operating Activities 3357 3959 5616 6686 7082 3907 2196 6555 6170 8985 4959
Cash Flow from Investing Activities -2635 -2367 -2866 -4372 -4222 -3371 -681 -2589 536 -5725 -7944
Cash Flow from Financing Activities -665 507 -1187 -1889 -2285 -1539 -2731 -5715 -5980 -5193 2376
Net Cash Inflow / Outflow 57 2099 1563 426 575 -1003 -1215 -1749 726 -1934 -608
Closing Cash & Cash Equivalent 2069 4359 7286 8032 8642 7906 7062 5677 6273 4508 4624

Sun Pharma Inds. Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 14.4 15.17 21.92 18.89 29.03 8.73 11.11 15.69 12.1 13.64 35.32
CEPS(Rs) 18.4 20.7 32.27 27.82 37.93 16.95 20.68 26.01 18.19 23.13 46.22
DPS(Rs) 2.5 1.5 3 1 3.5 2 2.75 4 7.5 10 11.5
Book NAV/Share(Rs) 72.37 89.44 123.49 137.03 152.7 159.69 172.59 188.66 193.65 200.11 233.38
Core EBITDA Margin(%) 42.69 43.01 28.37 28.64 30.66 10.81 11.14 11.74 13.78 14.71 15.44
EBIT Margin(%) 38.05 28.42 25.24 24.9 29.92 7.81 7.75 8.94 4.78 6.86 12.9
Pre Tax Margin(%) 37.68 28.15 23.14 23.07 28.65 6.79 6.76 8.43 4.55 6.67 12.67
PAT Margin (%) 30.3 23.83 19.84 19.86 24.82 5.02 5.7 7.05 3.72 5.07 11.53
Cash Profit Margin (%) 33.24 26.35 24.16 23.5 28.82 7.94 8.81 10.5 7.1 8.26 14.94
ROA(%) 19.61 16.21 14.6 11.39 14.08 4.24 5.17 6.58 3.54 5.2 11.85
ROE(%) 25.53 23.15 24.89 19.32 22.51 6.85 8.05 9.66 4.98 7.21 16.46
ROCE(%) 31.39 25.46 25.06 18.64 21.48 8.4 8.68 10.07 5.66 9.28 17.24
Receivable days 71.46 51.72 48.2 76.12 80.78 53.53 54.1 56.22 54.88 53.09 53.89
Inventory Days 74.22 63.92 57.99 77.46 76.61 48.88 47.84 48.4 50.1 48.68 47.78
Payable days 179.49 156.28 125.09 203.18 178.34 227.43 206.74 152.86 158.71 149.21 174.1
PER(x) 28.41 37.8 46.64 43.38 23.69 56.72 43.14 22.44 49.38 67.07 27.84
Price/Book(x) 5.65 6.41 8.28 5.98 4.5 3.1 2.78 1.87 3.09 4.57 4.21
Dividend Yield(%) 0.31 0.26 0.29 0.12 0.51 0.4 0.57 1.14 1.26 1.09 1.17
EV/Net Sales(x) 7.16 7.07 7.66 6.85 5.1 4.52 4.07 2.63 4.2 5.57 5.38
EV/Core EBITDA(x) 15.32 15.06 24.92 21.84 14.91 18.51 16.12 11.32 15.1 19.03 19.24
Net Sales Growth(%) 40.9 42.31 70.34 2.62 11.38 -15.63 10.03 12.98 2.01 15.39 13.53
EBIT Growth(%) 28.95 5.97 50.95 1.6 33.18 -57.7 9.23 21.69 -44.64 56.71 107.88
PAT Growth(%) 14.21 11.6 41.49 3.07 38.53 -67.23 24.98 30.46 -45.43 49.07 151.36
EPS Growth(%) 12.28 5.31 44.5 -13.82 53.67 -69.91 27.19 41.25 -22.87 12.7 158.91
Debt/Equity(x) 0.02 0.14 0.35 0.26 0.27 0.27 0.25 0.18 0.08 0.02 0.11
Current Ratio(x) 4.05 3.12 1.79 2.28 1.84 1.59 1.79 2.02 1.89 2.03 2
Quick Ratio(x) 3.14 2.6 1.44 1.79 1.46 1.25 1.34 1.51 1.33 1.51 1.47
Interest Cover(x) 101.13 104.67 12.06 13.56 23.63 7.72 7.86 17.55 20.79 36.19 55.7
Total Debt/Mcap(x) 0 0.02 0.04 0.04 0.06 0.09 0.09 0.1 0.03 0 0.03

Sun Pharma Inds. Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 54.48 54.48 54.48 54.48 54.48 54.48 54.48 54.48 54.48 54.48
FII 13 14.44 14.95 15.99 16.87 16.89 16.48 16.79 17.07 17.72
DII 21 20.02 19.66 19.64 19.14 19.24 19.75 19.67 19.52 18.82
Public 11.53 11.06 10.91 9.89 9.52 9.39 9.29 9.07 8.92 8.97
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 27% CAGR over last 5 years
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 10% over the last 3 years.
  • Debtor days have increased from 149.21 to 174.1days.
  • Stock is trading at 5.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Sun Pharma Inds. News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!